Naunyn-Schmiedeberg's Archives of Pharmacology · Nov 14, 2026

Neuropharmacology of omega-3 long-chain polyunsaturated fatty acids in neurodegenerative diseases: mechanisms, multi-omics evidence, and clinical translation

By Ali S, Ullah A

Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, involve progressive neuronal dysfunction associated with neuroinflammation, oxidative stress, mitochondrial impairment, defective proteostasis, and synaptic failure. Although symptomatic treatment remains central, anti-amyloid therapies can modestly slow clinical decline in selected patients with early Alzheimer’s disease. This review critically evaluates the neuropharmacological evidence for omega-3 long-chain polyunsaturated fatty acids, particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and the barriers to their clinical translation. We narratively synthesized preclinical, observational, and interventional clinical evidence, focusing on membrane organization, inflammatory resolution, mitochondrial and redox homeostasis, autophagy, proteostasis, neuronal signaling, and factors contributing to heterogeneous clinical outcomes. Preclinical studies support context-dependent effects of DHA and EPA on neuronal membranes, inflammatory signaling, mitochondrial function, redox balance, autophagy, and synaptic plasticity. Human evidence is less consistent: observational studies generally report favorable associations between omega-3 status and neurological outcomes, whereas randomized trials show null, modest, or subgroup-dependent effects. Outcomes vary with disease stage, baseline omega-3 status, formulation, dose, treatment duration, genotype, and endpoint selection. Uncertain central nervous system exposure and limited pharmacokinetic and target-engagement data remain major translational barriers. Omega-3 long-chain polyunsaturated fatty acids are biologically plausible neuropharmacological modulators, but current evidence does not establish DHA or EPA as broadly effective disease-modifying treatments for neurodegenerative diseases. Future trials should prioritize early-stage, biomarker-stratified populations, pharmacologically characterized formulations, adequate treatment duration, and clinically meaningful progression-related outcomes.

doi.org/10.1007/s00210-026-06086-yPubMed 43033255Interventions

AgingResearch.News